ProMetic Life Sciences Inc. (TSE:PLI)‘s stock had its “outperform” rating reiterated by analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday. They presently have a C$4.70 price objective on the stock. Royal Bank Of Canada’s target price would indicate a potential upside of 76.03% from the stock’s current price.

Several other research analysts also recently commented on PLI. CIBC reduced their target price on ProMetic Life Sciences from C$5.00 to C$4.85 in a report on Thursday, August 25th. TD Securities reaffirmed a “speculative buy” rating and set a C$4.50 price objective on shares of ProMetic Life Sciences in a report on Wednesday, November 16th. Canaccord Genuity upped their price objective on ProMetic Life Sciences from C$4.50 to C$4.75 and gave the stock a “buy” rating in a report on Friday. Scotiabank reaffirmed an “outperform” rating and set a C$5.00 price objective on shares of ProMetic Life Sciences in a report on Thursday, October 13th. Finally, Bloom Burton reaffirmed a “hold” rating on shares of ProMetic Life Sciences in a report on Thursday, October 13th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of C$4.84.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences (TSE:PLI) traded down 3.75% on Tuesday, hitting $2.57. The stock had a trading volume of 1,408,282 shares. The company’s 50 day moving average price is $2.88 and its 200-day moving average price is $2.93. The company’s market cap is $1.55 billion. ProMetic Life Sciences has a 12-month low of $1.88 and a 12-month high of $3.62.

About ProMetic Life Sciences

ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.